Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Grazyna Lieberman"'
Autor:
Stephen J. Ruberg, Francois Beckers, Rob Hemmings, Peter Honig, Telba Irony, Lisa LaVange, Grazyna Lieberman, James Mayne, Richard Moscicki
Publikováno v:
Nature Reviews Drug Discovery. 22:235-250
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8687c7ea90266f5aec946075753bc5c2
https://doi.org/10.1038/s41573-023-00638-0
https://doi.org/10.1038/s41573-023-00638-0
Publikováno v:
BMJ Evidence-Based Medicine. 24:95-98
Electronic health records (EHRs) have changed how medical information is captured, and they have the potential to be a rich source of information to improve drug development and clinical care. Accelerated in USA by the Health Information Technology f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c05baaef4f55dcf24aa6a976ece32093
https://doi.org/10.1136/bmjebm-2018-111111
https://doi.org/10.1136/bmjebm-2018-111111
Publikováno v:
Contemporary Clinical Trials. 38:235-244
Purpose To expedite drug development, we propose a two-step decision-making process that utilizes interim efficacy results from a comparative phase 2 trial to determine whether to accelerate subsequent phase 3 preparations, and final analysis to ulti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::425bea92320272387e1accb1573092c0
https://doi.org/10.1016/j.cct.2014.05.006
https://doi.org/10.1016/j.cct.2014.05.006
Autor:
Thomas Bengtsson, Jane Fridlyand, Howard Mackey, Paul Delmar, Grazyna Lieberman, Ru-Fang Yeh, Greg Spaniolo
Publikováno v:
Contemporary Clinical Trials. 36:624-635
In the past decade, the cost of drug development has increased significantly. The estimates vary widely but frequently quoted numbers are staggering-it takes 10-15 years and billions of dollars to bring a drug to patients. To a large extent this is d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdfdd30d1ca1a91eb8a6e3146bf88a64
https://doi.org/10.1016/j.cct.2013.04.006
https://doi.org/10.1016/j.cct.2013.04.006
Publikováno v:
Contemporary Clinical Trials. 32:856-863
Over the past decade many signaling pathways have been identified and implicated in cancer development. This has lead to rational drug development of many new molecules that target specific nodes on one or more signaling pathways. It is now believed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e49bf8a07838a230810e10da671824
https://doi.org/10.1016/j.cct.2011.06.005
https://doi.org/10.1016/j.cct.2011.06.005
Publikováno v:
Clinical Breast Cancer. 6:247-252
Background Hormone receptor (HR) and HER2 signaling pathways are involved in the regulation of breast cancer proliferation. The impact of HR status on the clinical outcome of patients with HER2-overexpressing disease treated with the monoclonal antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f80a1ef22d7ee2441b439019857af2b
https://doi.org/10.3816/cbc.2005.n.027
https://doi.org/10.3816/cbc.2005.n.027
Autor:
William Novotny, Charles S. Greenberg, Kimberly L. Blackwell, Herbert Hurwitz, Mark W. Dewhirst, Grazyna Lieberman, Stacey A. Snyder
Publikováno v:
Cancer. 101:77-82
BACKGROUND Fibrin formation is required for tumor angiogenesis, metastasis, and invasion. D-dimer, a fibrin degradation product, is produced when crosslinked fibrin is degraded by plasmin. The current study prospectively examined D-dimer levels in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e4505949afabe63abc369a0a2f58b6c
https://doi.org/10.1002/cncr.20336
https://doi.org/10.1002/cncr.20336
Autor:
Clifford A. Hudis, Deborah Keefe, Debasish Tripathy, Virginia E. Paton, Grazyna Lieberman, Andrew D. Seidman
Publikováno v:
Clinical breast cancer. 5(4)
Trastuzumab improves time to disease progression (TTP) and survival when added to chemotherapy for HERpositive metastatic breast cancer (MBC), but it is associated with infrequent cardiac dysfunction (CD). We analyzed data from a previous pivotal ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a10c3e1b690a026f111ba47fb8679b
https://pubmed.ncbi.nlm.nih.gov/15507176
https://pubmed.ncbi.nlm.nih.gov/15507176
Autor:
Ludger Banken, Grazyna Lieberman, Rene Bruno, Pamela M. Klein, Jian-Feng Lu, Carla Washington
Publikováno v:
Cancer chemotherapy and pharmacology. 56(4)
Purpose: To characterize the population pharmacokinetics of trastuzumab in patients with metastatic breast cancer. Methods: A nonlinear mixed effect model was based on pharmacokinetic data from phase I, II, and III studies of 476 patients. The phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f3f12ffb669721fe847f2c75a6f87e
https://pubmed.ncbi.nlm.nih.gov/15868146
https://pubmed.ncbi.nlm.nih.gov/15868146
Autor:
John G. Fryer, Arthur T. Evans, Robert A. McNutt, Anne Jackman, Nortin M. Hadler, Timothy S. Carey, William D. Kalsbeek, Grazyna Lieberman
Publikováno v:
Spine. 21(3)
Study design Telephone interviews were conducted with a random sample of adults in 4437 North Carolina households. The response rate was 79%. Objective The prevalence of low back pain and the correlates of care-seeking in a defined population were ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c09d9b9647eb8d50a7ee0eb2ebf6e74
https://pubmed.ncbi.nlm.nih.gov/8742211
https://pubmed.ncbi.nlm.nih.gov/8742211